Collectively, approaches that disrupt CD47-SIRPαpathway represent a promising strategy to facilitate hematoma resolution.Anti-CD47 antibodies such as magrolimab have advanced to phase III clinicaltrials for myelodysplastic syndrome and acute myeloid leukemia, providing aconceptual framework for application in ICH [53, 54]. This evidence concerns the gene CD47 and acute myeloid leukemia.